Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib.

× No keyword cloud information.

11 in total

Review 1. Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.

Authors: Emanuel Raschi; Fabrizio De Ponti
Journal: Front Pharmacol Date: 2019-10-24 Impact factor: 5.810

2. Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia.

Authors: Meteb H Al-Foheidi; Asem Mohammed Albeshri; Safwan Noor Moamenkahan; Abdulmajid Mohammed Abdullah; Muhannad Sadaqa Abualola; Muath Hamed Alharbi; Ahmed A Refa; Ali M Bayer; Ahmed Y Shaheen; Syed Sameer Aga; Muhammad Anwar Khan; Mubarak M Al-Mansour; Ezzeldin M Ibrahim
Journal: Mol Clin Oncol Date: 2022-06-01

3. Pseudocirrhosis Due to Desmoplastic Response to Chemotherapy in Breast Cancer Liver Metastases.

Authors: Kazuhide Takata; Ai Mogi; Ryo Yamauchi; Satoshi Shakado; Fumihito Hirai
Journal: Cureus Date: 2022-05-25

Review 4. Other types of diffuse liver disease: is there a way to do it?

Authors: Hilton Leao Filho; Camila Vilela de Oliveira; Natally Horvat
Journal: Abdom Radiol (NY) Date: 2020-11

Review 5. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.

Authors: Sarah L Sammons; Donna L Topping; Kimberly L Blackwell
Journal: Curr Cancer Drug Targets Date: 2017 Impact factor: 3.428

6. Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report.

Authors: Alyssa Schlotman; Adam Stater; Kyle Schuler; Judd Heideman; Vandana Abramson
Journal: Case Rep Oncol Date: 2020-03-24

7. Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study.

Authors: Daniel C Beachler; Cynthia de Luise; Aziza Jamal-Allial; Ruihua Yin; Devon H Taylor; Ayako Suzuki; James H Lewis; James W Freston; Stephan Lanes
Journal: BMC Cancer Date: 2021-01-25 Impact factor: 4.430

Review 8. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer.

Authors: Marc Thill; Marcus Schmidt
Journal: Ther Adv Med Oncol Date: 2018-09-03 Impact factor: 8.168

9. Palbociclib-Induced Liver Failure.

Authors: Rami Atallah; Nathaniel A Parker; Karl Hamouche; Quoc V Truong; Megan Dingwall
Journal: Kans J Med Date: 2020-04-17

10. Pseudocirrhosis in Breast Cancer - Experience From an Academic Cancer Center.

Authors: Dharmesh Gopalakrishnan; Ain Shajihan; Andrei S Purysko; Jame Abraham
Journal: Front Oncol Date: 2021-07-02 Impact factor: 6.244